Biotech News
Related news
ROIVRoivant2026-04-02 09:00 EST
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
ROIVRoivant2026-02-06 12:00 EST
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
Roivant
Vant Operating Model Roivant develops and commercializes medicines through focused subsidiaries known as Vants. The structure gives individual programs dedicated teams while retaining access to the parent company's capital, development and commercialization capabilities. Brepocitinib Autoimmune Franchise Brepocitinib is an oral JAK1/TYK2...
Recent company news
ROIVRoivant2026-09-06 05:00 EST
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
ROIVRoivant2026-08-27 19:29 EST
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
ROIVRoivant2026-08-27 19:29 EST
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
ROIVRoivant2026-08-26 15:12 EST
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
ROIVRoivant2026-08-06 11:00 EST
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
Stock data
- Close
- 39.98 USD
- Market cap
- 20.32B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States